Olmesartan Lek-Am (Olmesartan Medoxomil)

Olmesartan medoxyl, the active ingredient in Olmesartan Lek‑Am, is a angiotensin II receptor blocker presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmesartan Lek‑Am as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Lek‑Am as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Lek‑Am is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure levels in adults. - Diabetic nephropathy (off‑label): may slow progression of kidney damage associated with diabetes. - Heart failure (off‑label): used as part of combination therapy to improve cardiac workload. - Stroke prevention (off‑label), reduces risk of recurrent ischemic events in high‑risk patients.

Common Side Effects: - Dizziness or light‑headed ​​​​​  ​  ​  ​  ​ - Headache  - Fatigue  - Nasal congestion  - Diarrhoea  - Cough 

Serious or Rare Side Effects: - Angio‑ang  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ - Severe hypotension  - Acute kidney injury  - Hyperkalemia  - Liver enzyme elevation  - Anaphylaxis  - Stevens‑Johnson syndrome

Olmesartan Lek‑Am should be used  ​  ​  ... 

-      ...  -   …